TG Therapeutics raises BRIUMVI revenue guidance to $585M, Q3 net income $390.9M

TG THERAPEUTICS, INC.

2025-Q3 EPS reported $2.62 revenue$423,713,000

Q3 2025 total revenue $161.7M, BRIUMVI US net revenue $152.9M up 84% YoY.
Raises FY2025 BRIUMVI US net revenue target to ~$585M (prior $570-575M) and global target to $600M.
Q3 net income $390.9M includes $365M non-recurring tax benefit; net income $3.9M in Q3 2024.
Completed $100M buyback (3.5M shares at avg $28.55); authorized new $100M repurchase program.
Phase 3 subcutaneous ublituximab enrollment commenced; ENHANCE trial for consolidated IV dosing fully enrolled.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.